8-K: The Oncology Institute Reports 20.1% Revenue Increase in Q4 2023, But Net Loss Widens

The Oncology Institute (TOI) announced a 20.1% increase in revenue for the fourth quarter of 2023, alongside a widened net loss and provided financial guidance for 2024.

Summary

• The Oncology Institute (TOI) reported its financial results for the fourth quarter and full year ended December 31, 2023.
• Consolidated revenue for Q4 2023 reached $86 million, a 20.1% increase compared to the same quarter in the previous year.
• Gross profit for Q4 2023 was $14 million, an 8.0% decrease compared to Q4 2022.
• The net loss for Q4 2023 was $18.8 million, compared to a net loss of $11.0 million in the prior year quarter.
• Adjusted EBITDA for Q4 2023 was $(6.3) million, compared to $(4.6) million for the prior year quarter.
• For the full year 2023, consolidated revenue was $324 million, a 28.4% increase year-over-year.
• Full year gross profit was $60 million, a 14.4% increase year-over-year.
• The net loss for the full year 2023 was $83.1 million, compared to a net income of $0.152 million in the prior year.
• Adjusted EBITDA for the full year 2023 was $(25.8) million, compared to $(23.5) million in the prior year.
• The company ended the year with 69 clinics and 119 employed providers.
• TOI has provided 2024 guidance with revenue expected to be between $400 to $415 million and adjusted EBITDA between $(8) to $(18) million.

Sentiment

Score: 4

Explanation: While the company shows strong revenue growth, the widening net losses and negative EBITDA, along with negative guidance for 2024, temper the overall sentiment. The company is making progress in some areas, but profitability remains a significant concern.

Positives

• Consolidated revenue increased by 20.1% in Q4 2023 and 28.4% for the full year 2023.
• Patient services revenue grew by 17.0% in Q4 2023 and 28.0% for the full year.
• Dispensary revenue increased by 27.8% in Q4 2023 and 30.9% for the full year.
• SG&A expenses decreased as a percentage of revenue in both Q4 and the full year 2023.
• The company successfully remediated a material weakness in internal controls.
• TOI signed a full-risk capitated contract in South Florida, effective January 1, 2024.
• Revenue per capitated member increased by 10.5% year-over-year to $39.5 PMPY.

Negatives

• Gross profit decreased by 8.0% in Q4 2023, despite increased revenue.
• Net loss widened to $18.8 million in Q4 2023 and $83.1 million for the full year.
• Adjusted EBITDA was negative for both Q4 2023 and the full year 2023.
• The company experienced a goodwill impairment charge in both Q4 and the full year 2023.
• The company's 2024 adjusted EBITDA guidance is negative, ranging from $(8) to $(18) million.

Risks

• The company's future performance is subject to risks and uncertainties, including those disclosed in its SEC filings.
• The 2024 outlook does not account for unanticipated developments or changes in the operating environment.
• The outlook assumes a largely reopened global market, which could be negatively impacted by closures or restrictive measures.
• The company's ability to achieve its financial guidance is subject to various risks and uncertainties.
• Fluctuations in the cost of oral and IV drugs can impact gross profit.

Future Outlook

TOI expects 2024 revenue to be between $400 and $415 million and adjusted EBITDA to be between $(8) and $(18) million. The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of TOI's acquisitions, dispositions or financings.

Management Comments

• Daniel Virnich, CEO of TOI, stated he is very pleased with the company's performance in the fourth quarter of 2023.
• The CEO highlighted the strong growth, expanded gross margin, and reduced SG&A in Q4 2023.
• The full-risk capitated contract in South Florida was described as a significant milestone for TOI.
• Management believes their ability to grow topline while improving margins lays the groundwork for continued success in 2024 and beyond.

Industry Context

This announcement reflects the ongoing challenges and opportunities in the value-based oncology care sector, where companies are striving to balance growth with profitability. The move towards capitated contracts and the expansion of pharmacy services are common strategies in this industry to improve financial performance and patient outcomes.

Comparison to Industry Standards

• While TOI's revenue growth is strong, the continued net losses and negative adjusted EBITDA are concerning when compared to established players in the healthcare sector.
• Companies like US Oncology and McKesson Specialty Health, which are also involved in oncology care, often report positive EBITDA and net income, indicating TOI has room for improvement in operational efficiency and cost management.
• The move to full-risk capitated contracts is a trend in the industry, but the success of these contracts is crucial for long-term profitability, and TOI's performance in this area will be closely watched.
• TOI's revenue per capitated member of $39.5 PMPY is a key metric, but it needs to be compared against industry benchmarks to assess its competitiveness and profitability.

Stakeholder Impact

• Shareholders may be concerned about the widening net losses and negative adjusted EBITDA.
• Employees may be impacted by the company's restructuring and cost rationalization programs.
• Customers (patients) may benefit from the company's expansion of services and value-based care model.
• Suppliers may be affected by the company's cost management efforts.
• Creditors will be monitoring the company's financial performance closely.

Next Steps

• TOI will host a conference call on March 27, 2024, to discuss the results and outlook.
• The company will continue to focus on growing its capitated contracts and expanding its pharmacy services.
• TOI will need to demonstrate improved cost management and operational efficiency to achieve profitability.

Key Dates

Keywords

Oncology, Healthcare, Financial Results, Revenue, EBITDA, Net Loss, Capitated Contracts, Pharmacy, Guidance, Gross Profit